Endece Neural receives grant from the National Multiple Sclerosis Society

Special to The Freeman

Sept. 27, 2013

MEQUON – Endece Neural LLC on Friday said it has received a $225,000 grant from the National Multiple Sclerosis Society to continue its work on a multiple sclerosis treatment.

The grant money will help Endece continue to develop its lead compound, which the company says could improve the lives of multiple sclerosis patients, according to a company statement.

MS patients’ immune systems attack the myelin coating that protects the brain’s nerve cells. The damage disrupts the ability of parts of the nervous system to communicate.

"Currently, available therapies for MS are designed to slow the progression of the disease by reducing inflammation, but do not activate key target cells that can manufacture myelin," said Steven H. Ney, vice president of discovery at Endece Neural.

"We are pleased to partner with innovators like Endece Neural to enable continued development of their therapeutic programs," said Timoth Coetzee, chief research officer at the National MS Society.